@article{natale_angiotensin-converting_2024,
	title = {Angiotensin-converting enzyme inhibitors, statins and the polypill in cardiovascular diseases prevention: ignorance is bliss or not?},
	volume = {42},
	issn = {02636352},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186847516&doi=10.1097%2fHJH.0000000000003687&partnerID=40&md5=4a0b08f9226105ba355b3ab5def98471},
	doi = {10.1097/HJH.0000000000003687},
	abstract = {The polypill strategy, which combines several medicines that simultaneously control different risk factors/diseases in a single pill, is one of the approaches used in cardiovascular therapy. In different guidelines, this one-pill combination therapy is suggested as first-line step in disease management. Because the cardiovascular diseases (CVD) pandemia, prevention is essential. The approaches that could improve adherence are of great importance to achieve health, social and economical benefits. However, direct or indirect experience of adverse drug reaction is often the reason for discontinuation, with serious fatal and non-fatal consequences especially for a polypill. Angiotensin-converting enzyme inhibitors (ACEi) and statins are the most prescribed medications in CVD prevention. It is well known that both drugs may have adverse effects that induce discontinuation. Often, the personal awareness of these effects is a reason for self-discontinuation. In this study an analysis of the ACEi/statin awareness is reported. Is it potentially harmful for polypill? Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.},
	language = {English},
	number = {4},
	journal = {Journal of Hypertension},
	author = {Natale, Francesco and Golino, Paolo and Cimmino, Giovanni},
	year = {2024},
	pmid = {38441187},
	note = {Publisher: Lippincott Williams and Wilkins
Type: Article},
	keywords = {Angiotensin-Converting Enzyme Inhibitors, Article, Cardiovascular Diseases, Combined Modality Therapy, Disease Management, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, awareness, cardiovascular disease, cardiovascular risk, dipeptidyl carboxypeptidase inhibitor, disease management, human, hydroxymethylglutaryl coenzyme A reductase inhibitor, multimodality cancer therapy, practice guideline, prophylaxis, risk factor},
	pages = {746 -- 748},
}

{"_id":"vDqxKoLfaZvsXoENg","bibbaseid":"natale-golino-cimmino-angiotensinconvertingenzymeinhibitorsstatinsandthepolypillincardiovasculardiseasespreventionignoranceisblissornot-2024","author_short":["Natale, F.","Golino, P.","Cimmino, G."],"bibdata":{"bibtype":"article","type":"article","title":"Angiotensin-converting enzyme inhibitors, statins and the polypill in cardiovascular diseases prevention: ignorance is bliss or not?","volume":"42","issn":"02636352","url":"https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186847516&doi=10.1097%2fHJH.0000000000003687&partnerID=40&md5=4a0b08f9226105ba355b3ab5def98471","doi":"10.1097/HJH.0000000000003687","abstract":"The polypill strategy, which combines several medicines that simultaneously control different risk factors/diseases in a single pill, is one of the approaches used in cardiovascular therapy. In different guidelines, this one-pill combination therapy is suggested as first-line step in disease management. Because the cardiovascular diseases (CVD) pandemia, prevention is essential. The approaches that could improve adherence are of great importance to achieve health, social and economical benefits. However, direct or indirect experience of adverse drug reaction is often the reason for discontinuation, with serious fatal and non-fatal consequences especially for a polypill. Angiotensin-converting enzyme inhibitors (ACEi) and statins are the most prescribed medications in CVD prevention. It is well known that both drugs may have adverse effects that induce discontinuation. Often, the personal awareness of these effects is a reason for self-discontinuation. In this study an analysis of the ACEi/statin awareness is reported. Is it potentially harmful for polypill? Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.","language":"English","number":"4","journal":"Journal of Hypertension","author":[{"propositions":[],"lastnames":["Natale"],"firstnames":["Francesco"],"suffixes":[]},{"propositions":[],"lastnames":["Golino"],"firstnames":["Paolo"],"suffixes":[]},{"propositions":[],"lastnames":["Cimmino"],"firstnames":["Giovanni"],"suffixes":[]}],"year":"2024","pmid":"38441187","note":"Publisher: Lippincott Williams and Wilkins Type: Article","keywords":"Angiotensin-Converting Enzyme Inhibitors, Article, Cardiovascular Diseases, Combined Modality Therapy, Disease Management, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, awareness, cardiovascular disease, cardiovascular risk, dipeptidyl carboxypeptidase inhibitor, disease management, human, hydroxymethylglutaryl coenzyme A reductase inhibitor, multimodality cancer therapy, practice guideline, prophylaxis, risk factor","pages":"746 – 748","bibtex":"@article{natale_angiotensin-converting_2024,\n\ttitle = {Angiotensin-converting enzyme inhibitors, statins and the polypill in cardiovascular diseases prevention: ignorance is bliss or not?},\n\tvolume = {42},\n\tissn = {02636352},\n\turl = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186847516&doi=10.1097%2fHJH.0000000000003687&partnerID=40&md5=4a0b08f9226105ba355b3ab5def98471},\n\tdoi = {10.1097/HJH.0000000000003687},\n\tabstract = {The polypill strategy, which combines several medicines that simultaneously control different risk factors/diseases in a single pill, is one of the approaches used in cardiovascular therapy. In different guidelines, this one-pill combination therapy is suggested as first-line step in disease management. Because the cardiovascular diseases (CVD) pandemia, prevention is essential. The approaches that could improve adherence are of great importance to achieve health, social and economical benefits. However, direct or indirect experience of adverse drug reaction is often the reason for discontinuation, with serious fatal and non-fatal consequences especially for a polypill. Angiotensin-converting enzyme inhibitors (ACEi) and statins are the most prescribed medications in CVD prevention. It is well known that both drugs may have adverse effects that induce discontinuation. Often, the personal awareness of these effects is a reason for self-discontinuation. In this study an analysis of the ACEi/statin awareness is reported. Is it potentially harmful for polypill? Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.},\n\tlanguage = {English},\n\tnumber = {4},\n\tjournal = {Journal of Hypertension},\n\tauthor = {Natale, Francesco and Golino, Paolo and Cimmino, Giovanni},\n\tyear = {2024},\n\tpmid = {38441187},\n\tnote = {Publisher: Lippincott Williams and Wilkins\nType: Article},\n\tkeywords = {Angiotensin-Converting Enzyme Inhibitors, Article, Cardiovascular Diseases, Combined Modality Therapy, Disease Management, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, awareness, cardiovascular disease, cardiovascular risk, dipeptidyl carboxypeptidase inhibitor, disease management, human, hydroxymethylglutaryl coenzyme A reductase inhibitor, multimodality cancer therapy, practice guideline, prophylaxis, risk factor},\n\tpages = {746 -- 748},\n}\n\n\n\n\n\n\n\n","author_short":["Natale, F.","Golino, P.","Cimmino, G."],"key":"natale_angiotensin-converting_2024","id":"natale_angiotensin-converting_2024","bibbaseid":"natale-golino-cimmino-angiotensinconvertingenzymeinhibitorsstatinsandthepolypillincardiovasculardiseasespreventionignoranceisblissornot-2024","role":"author","urls":{"Paper":"https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186847516&doi=10.1097%2fHJH.0000000000003687&partnerID=40&md5=4a0b08f9226105ba355b3ab5def98471"},"keyword":["Angiotensin-Converting Enzyme Inhibitors","Article","Cardiovascular Diseases","Combined Modality Therapy","Disease Management","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","awareness","cardiovascular disease","cardiovascular risk","dipeptidyl carboxypeptidase inhibitor","disease management","human","hydroxymethylglutaryl coenzyme A reductase inhibitor","multimodality cancer therapy","practice guideline","prophylaxis","risk factor"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero-group/science_et_ignorance/1340424","dataSources":["zX4acseCDM6D58AW7"],"keywords":["angiotensin-converting enzyme inhibitors","article","cardiovascular diseases","combined modality therapy","disease management","humans","hydroxymethylglutaryl-coa reductase inhibitors","awareness","cardiovascular disease","cardiovascular risk","dipeptidyl carboxypeptidase inhibitor","disease management","human","hydroxymethylglutaryl coenzyme a reductase inhibitor","multimodality cancer therapy","practice guideline","prophylaxis","risk factor"],"search_terms":["angiotensin","converting","enzyme","inhibitors","statins","polypill","cardiovascular","diseases","prevention","ignorance","bliss","natale","golino","cimmino"],"title":"Angiotensin-converting enzyme inhibitors, statins and the polypill in cardiovascular diseases prevention: ignorance is bliss or not?","year":2024}